Medtech company Becton, Dickson and Company (BD) has seen its second generation BD Nano pen needles given 510(k) clearance by the U.S. Food and Drug Administration.
The pen needles aim to offer people who inject diabetes medications are more reliable subcutaneous delivery of their medication. Proper injection technique is critical to insulin's consistent absorption and there are several factors that can inhibit predictable insulin uptake, including accidental intramuscular injections, which can be caused by greater than required injection force.
The pen needles aim to mitigate the risks resulting from user injection force variability through its contoured needle base and compensate for variable injection forces by first concentrating, then distributing pressure closely around the injection site.
Stanislav Glezer, global vice president of Medical Affairs for BD, said: "The launch of BD Nano 2nd gen pen needles reinforces BD's commitment to providing the most advanced solutions possible for people with diabetes to help achieve better clinical management of insulin use. In addition to the added clinical benefits the latest BD innovation brings, the new ergonomic pen needle features can help people feel more comfortable with their injection experience."
FDA 510(k) clearance will enable BD Nano 2nd gen pen needles to be commercially available in mid-2019.
